for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pacira Biosciences Inc

PCRX.OQ

Latest Trade

37.16USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

34.64

 - 

54.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
37.16
Open
--
Volume
--
3M AVG Volume
10.88
Today's High
--
Today's Low
--
52 Week High
54.92
52 Week Low
34.64
Shares Out (MIL)
41.64
Market Cap (MIL)
1,547.16
Forward P/E
25.87
Dividend (Yield %)
--

Next Event

Q3 2019 Pacira Biosciences Inc Earnings Release

Latest Developments

More

Pacira BioSciences Reports Q2 Non-Gaap Earnings Per Share $0.41

Consonance Capital Management Reports Stake Of 6.8% In Pacira Biosciences As Of July 9

Pacira Biosciences Reports Q1 Loss Per Share $0.07

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pacira Biosciences Inc

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Industry

Biotechnology & Drugs

Contact Info

5 Sylvan Way Ste 300

+1.973.2543560

http://www.pacira.com/

Executive Leadership

David M. Stack

Chairman of the Board, Chief Executive Officer

Max Reinhardt

President

Charles A. Reinhart

Chief Financial Officer

Kristen Williams

Chief Administrative Officer, General Counsel, Secretary

Charles Laranjeira

Chief Technical Officer

Key Stats

2.43 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.3K

2017

0.3K

2018

0.3K

2019(E)

0.4K
EPS (USD)

2016

0.620

2017

0.210

2018

1.040

2019(E)

1.437
Price To Earnings (TTM)
203.03
Price To Sales (TTM)
4.15
Price To Book (MRQ)
4.53
Price To Cash Flow (TTM)
59.83
Total Debt To Equity (MRQ)
87.28
LT Debt To Equity (MRQ)
87.28
Return on Investment (TTM)
1.17
Return on Equity (TTM)
1.06

Latest News

BRIEF-Pacira Pharmaceuticals Reports Q4 GAAP EPS Of $0.11

* PACIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Pacira Says FDA ‍committee ‍Did Not Reach A Unanimous Decision For Exparel As A Nerve Block To Produce Regional Analgesia​

* PACIRA PHARMACEUTICALS STATEMENT ON FDA ADVISORY COMMITTEE FOR EXPAREL® FOR USE AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA

BRIEF-Pacira Pharmaceuticals Says FDA Advisory Committee To Review SNDA For Exparel

* PACIRA PHARMACEUTICALS STOCK TRADING HALTED; FDA ADVISORY COMMITTEE TO REVIEW SNDA FOR EXPAREL® AS A NERVE BLOCK FOR REGIONAL ANALGESIA Source text for Eikon: Further company coverage:

BRIEF-Pacira Pharma says FDA Posts Briefing Documents For Advisory Meeting Reviewing SNDA For Exparel

* PACIRA PHARMACEUTICALS INC - FDA POSTS BRIEFING DOCUMENTS FOR ADVISORY MEETING REVIEWING SNDA FOR EXPAREL AS A NERVE BLOCK FOR REGIONAL ANALGESIA

BRIEF-Wellstar And Pacira To Minimize Opioid Use Across Surgical Procedures

* WELLSTAR HEALTH SYSTEM AND PACIRA PHARMACEUTICALS ANNOUNCE PARTNERSHIP TO MINIMIZE OPIOID USE AND STANDARDIZE OUTCOMES ACROSS SURGICAL PROCEDURES Source text for Eikon: Further company coverage:

BRIEF-Pacira Pharmaceuticals Reports Preliminary 2017 Revenues Of $286.6 Million

* PACIRA PHARMACEUTICALS REPORTS PRELIMINARY 2017 REVENUES OF $286.6 MILLION

BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel

* Pacira announces FDA advisory committee meeting to review sNDA for Exparel as a nerve block for regional analgesia

BRIEF-Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11

* Pacira Pharmaceuticals Inc reports third quarter 2017 financial results

BRIEF-Pacira Pharma to invest up to $25 million in Tela Bio

* Committed to invest up to $25 million in Tela Bio, a privately-held surgical reconstruction company

BRIEF-Pacira Pharmaceuticals announces FDA acceptance of SNDA

* Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia

BRIEF-‍Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals ​

* Point72 Asset Management LP reports a 5.0 pct passive stake in Pacira Pharmaceuticals Inc as of Aug 21 - SEC filing Source text: (http://bit.ly/2io69IV) Further company coverage:

BRIEF-Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals

* Healthcor Management L.P. reports a 6.2 pct passive stake in Pacira Pharmaceuticals, as of Aug 3 - SEC filing Source text for Eikon: (http://bit.ly/2fEM3Jn) Further company coverage:

BRIEF-Pacira Pharma says data on Exparel published in medical journal

* Pacira announces publication of phase 4 study of exparel in patients undergoing total knee replacement in the journal of arthroplasty Source text for Eikon: Further company coverage:

BRIEF-Pacira announces topline phase 3 results for Exparel

* Pacira announces topline phase 3 results for Exparel as a single-dose nerve block

BRIEF-Pacira Pharma says President James Scibetta has resigned

* Pacira pharmaceuticals -james scibetta resigning as president to become ceo of an undisclosed private early-stage oncology company

BRIEF-Pacira Pharmaceuticals Inc reports Q1 GAAP loss per share $0.52

* Pacira pharmaceuticals, inc. Reports first quarter 2017 financial results

BRIEF-Trinity and Pacira announce collaboration to decrease opioid use nationwide

* Trinity Health and Pacira Pharmaceuticals announce collaboration to decrease opioid use nationwide

BRIEF-Pacira says phase 4 study shows its drug reduces opioid consumption and postsurgical pain in patients undergoing total knee arthroplasty

* Phase 4 study shows exparel versus active comparator reduces opioid consumption and postsurgical pain in patients undergoing total knee arthroplasty

BRIEF-Pacira Pharmaceuticals prices $300 mln aggregate principal amount of 2.375% convertible senior notes due 2022

* Pacira Pharmaceuticals announces pricing of $300 million aggregate principal amount of 2.375% convertible senior notes due 2022 Source text for Eikon: Further company coverage:

BRIEF-Pacira Pharmaceuticals announces proposed offering of $300 million aggregate principal amount of convertible senior notes

* Announces proposed offering of $300 million aggregate principal amount of convertible senior notes

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up